ReviewInternational journal of colorectal disease2004
Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature.
Review in International journal of colorectal disease, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803.Clinical cancer research : an official journal of the American Association for Cancer Research · 2009Trial
- Rectal Cancer: Exploring Predictive Biomarkers Through Molecular Pathways Involved in Carcinogenesis.Biology · 2024Review
- Research progress of DNA methylation in colorectal cancer (Review).Molecular medicine reports · 2024Review
- Overexpression of TP53 protein is associated with the lack of adjuvant chemotherapy benefit in patients with stage III colorectal cancer.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2020Article
- Are Colon and Rectal Cancer Two Different Tumor Entities? A Proposal to Abandon the Term Colorectal Cancer.International journal of molecular sciences · 2018Review
- Role of RAS mutation status as a prognostic factor for patients with advanced colorectal cancer treated with first-line chemotherapy based on fluoropyrimidines and oxaliplatin, with or without bevavizumab: A retrospective analysis.Molecular and clinical oncology · 2017Article
- Promoter CpG island methylation of RET predicts poor prognosis in stage II colorectal cancer patients.Molecular oncology · 2014Article
- MicroRNA binding site polymorphisms as biomarkers in cancer management and research.Pharmacogenomics and personalized medicine · 2014Review
- Impact of KRAS Mutation Status on Outcomes in Metastatic Colon Cancer Patients without Anti-Epidermal Growth Factor Receptor Therapy.Cancer research and treatment · 2013Article
- A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2011Article
- Prognostic value of colorectal cancer biomarkers.Cancers · 2011Article
- The Prognostic Impact of p53 Expression on Sporadic Colorectal Cancer Is Dependent on p21 Status.Cancers · 2011Article
- KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis.British journal of cancer · 2010Article
- Epithelial to mesenchymal transition is impaired in colon cancer cells with microsatellite instability.Gastroenterology · 2010Article
- KRAS mutation and microsatellite instability: two genetic markers of early tumor development that influence the prognosis of colorectal cancer.Annals of surgical oncology · 2010Article
- A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy.The oncologist · 2010Review
- Studies on p53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: major prognostic impact of proapoptotic BAX.British journal of cancer · 2007Article
- A novel multiplexing, polymerase chain reaction-based assay for the analysis of chromosome 18q status in colorectal cancer.The Journal of molecular diagnostics : JMD · 2005Article
- Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma.British journal of cancer · 2005Article
- Molecular detection of clinical colorectal cancer metastasis: how should multiple markers be put to use?International journal of colorectal disease · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn the Dukes' B and C stages of colorectal carcinoma there are considerable variations in the observed courses of the disease. Since post-operative chemotherapy in patients with Dukes' C (node-positive) colon carcinoma has been demonstrated to be effective in improving overall-survival, a more exact prognosis assessment gains additional significance and therapeutic relevance. DISCUSSION: One also hopes to derive improved prognostic factors from the clarification of the molecular pathogenesis. Because of its frequency and the accessibility and recognizability of its developmental stages colorectal carcinoma is among the best investigated of all solid tumors. Despite a multitude of suggested molecular candidate markers none of these changes has yet been able enter the everyday life of the clinic. However, it is to be expected that some of the molecular alterations presently discussed will gain importance before long in the clinical treatment of patients with colorectal carcinoma.
conclusionConsidering also our own findings, this review presents the latest developments in the scientific discussion of the tumor suppressor/oncogenes p53, k-ras, and DCC, biochemical determinants of the 5-fluorouracil metabolism, and defects of the DNA repair system.
Indexed as
Identifiers
12827409What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.